A Competitive Analysis of the Global Asthma and COPD Therapeutics Market
A Competitive Analysis of the Global Asthma and COPD Therapeutics Market
Novel Inhaler Devices and Formulations are Impetuses for Growth
RELEASE DATE
30-Oct-2014
30-Oct-2014
REGION
North America
North America
Research Code: MA2A-01-00-00-00
SKU: LS00101-NA-MR_16942
$3,950.00
In stock
SKU
LS00101-NA-MR_16942
Description
The research service assesses marketed and investigational products, as well as combination regimens, for asthma and chronic obstructive pulmonary disease (COPD). Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into bronchodilators, anti-inflammatories, and combination therapies of current global interest. Novel inhaler devices, formulations, and anti-inflammatories are key drivers for the market.
Table of Contents
Key Findings
Key Findings—Asthma
Key Findings—COPD
Overview of Product Launches and Pipeline Development
Key Companies to Watch
CEO’s Perspective
Methodology and Scope
Market Overview—Segmentation
Market Overview—Definitions
Prevalence of Asthma by Country/Region
Prevalence of COPD by Country/Region
Asthma Therapeutics Market—Marketed and Pipeline Products
Asthma Therapeutics Market—Marketed and Pipeline Products (continued)
Asthma Therapeutics Market—Key Marketed Product Synopsis
Asthma Therapeutics Market—Key Marketed Product Synopsis (continued)
Asthma Therapeutics Market—Key Pipeline Product Synopsis
Asthma Therapeutics Market—Key Pipeline Product Synopsis (continued)
COPD Therapeutics Market—Marketed and Pipeline Products
COPD Therapeutics Market—Marketed and Pipeline Products (continued)
COPD Therapeutics Market—Key Marketed Product Synopsis
COPD Therapeutics Market—Key Marketed Product Synopsis (continued)
COPD Therapeutics Market—Key Pipeline Product Synopsis
COPD Therapeutics Market—Key Pipeline Product Synopsis (continued)
Total Asthma and COPD Therapeutics Market—Projected Launch Timeline for Key Pipeline Drugs
Pivotal Phase 3 Trials
Estimated Product Launch Timeline—Striverdi Respimat for Asthma and COPD by Boehringer Ingelheim
Estimated Product Launch Timeline—Quilizumab for Asthma by Genentech
Estimated Product Launch Timeline—DuoResp Spiromax for Asthma and COPD by Teva Pharmaceuticals
Estimated Product Launch Timeline—Incruse Ellipta (umeclidinium) for COPD by GSK
Estimated Product Launch Timeline—Benralizumab for Asthma by AstraZeneca
Patent Expiration Timeline
Seebri Breezhaler by Novartis
Advair/Seretide by GSK
Xolair by Genentech and Novartis
Asmanex Twisthaler by Merck & Co.
Spiriva by Boehringer Ingelheim
AirFlu Sal/Forspiro by Sandoz (Novartis)
Incruse Ellipta by GSK
Benralizumab by AstraZeneca
Bosatria by GSK
PT003 by Pearl Therapeutics (AstraZeneca)
Conclusions
Legal Disclaimer
Decision Support Database—Global Prevalence of Smokers
Decision Support Database—Global Prevalence of Smokers (continued)
Decision Support Database—Population with COPD
Decision Support Database—Population with COPD (continued)
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Related Research
Popular Topics
This market insight provides a first-of-its-kind analysis of market sizing and revenue forecasts through 2016 for the prevalent Ebola virus. The number of people infected nears 10,000 globally, and the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have deemed this the worst outbreak due to the death toll nearing 5,000. The Ebola market is segmented by diagnostics and pharmaceuticals, and the diagnostics market includes both molecular methods and immunodiagnostics tests, of which a 2-year potential-revenue forecast is provided. Molecular methods will see wide adoption for the specificity, sensitivity, and rapidity of the tests. Competitive landscape and companies to watch chapters are provided.
No Index | No |
---|---|
Podcast | No |
Author | Sriram Radhakrishnan |
WIP Number | MA2A-01-00-00-00 |
Is Prebook | No |